AOLS: AI 评分 47/100 — AI 分析 (4月 2026)

Aeolus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing novel compounds for biodefense and various diseases. Their lead compound, AEOL 10150, targets acute radiation syndrome and chemical weapon exposure.

Key Facts: AI Score: 47/100 Sector: Healthcare

公司概况

概要：

Aeolus Pharmaceuticals, Inc. is a biopharmaceutical firm specializing in catalytic antioxidant compounds for biodefense and diseases like fibrosis, oncology, and CNS disorders. Their lead asset, AEOL 10150, addresses acute radiation syndrome, positioning them within a niche market of medical countermeasures and targeted therapies.

AOLS是做什么的？

Founded in 1994 and based in Mission Viejo, California, Aeolus Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing a platform of novel compounds. The company's primary focus is on creating medical countermeasures against nuclear, radiological, and chemical weapons, as well as treatments for diseases and disorders affecting the respiratory system, central nervous system, and oncology. Their lead compound, AEOL 10150, has completed two Phase I clinical trials and is being developed to combat the pulmonary sub-syndrome of acute radiation syndrome. It is also intended for use as a medical countermeasure against exposure to chemical vesicants and nerve agents. In addition to AEOL 10150, Aeolus is developing AEOL 11114B, AEOL 11203, and AEOL 11207 for the treatment of Parkinson's disease, and AEOL 20415 for treating infectious diseases. Aeolus Pharmaceuticals operates primarily in the United States, focusing on specialized drug development within the biodefense and targeted therapy sectors. The company aims to address unmet medical needs through its innovative platform of catalytic antioxidant compounds.

AOLS的投资论点是什么？

Aeolus Pharmaceuticals operates in a high-risk, high-reward sector, focusing on biodefense and niche disease treatments. The company's lead compound, AEOL 10150, targeting acute radiation syndrome, represents a significant potential value driver, contingent on successful clinical trials and regulatory approval. Further development of AEOL 11114B, AEOL 11203, and AEOL 11207 for Parkinson's disease, and AEOL 20415 for infectious diseases, could diversify the pipeline. However, the company's negative profit margin of -171.4% and gross margin of -38.8% highlight financial challenges. The company's small size and OTC listing also present liquidity and volatility risks. Investors should closely monitor clinical trial outcomes, regulatory milestones, and funding activities.

AOLS在哪个行业运营？

Aeolus Pharmaceuticals operates within the specialty and generic drug manufacturing industry, a segment characterized by intense competition and regulatory scrutiny. The market is driven by factors such as an aging population, increasing prevalence of chronic diseases, and advancements in drug development technologies. Companies like Aeolus face competition from larger pharmaceutical firms and other specialty drug developers. The industry is also subject to evolving regulatory landscapes, impacting drug approval processes and market access. Aeolus' focus on biodefense and niche disease treatments positions it within a specialized segment of this broader market.

Drug Manufacturers - Specialty & Generic

Healthcare

AOLS有哪些增长机遇？

Development of AEOL 10150 for Acute Radiation Syndrome: The global market for medical countermeasures against radiation exposure is projected to grow, driven by increasing concerns over nuclear threats and accidents. Successful completion of clinical trials and regulatory approval for AEOL 10150 could provide Aeolus with a significant revenue stream. The timeline for this growth opportunity depends on the progress of clinical trials and regulatory review, potentially spanning several years.
Expansion into Parkinson's Disease Treatment: The market for Parkinson's disease therapeutics is substantial and growing, driven by an aging population. Aeolus' development of AEOL 11114B, AEOL 11203, and AEOL 11207 represents an opportunity to tap into this market. Success in clinical trials and subsequent commercialization could lead to significant revenue growth. The timeline for this expansion depends on the progress of drug development and regulatory approvals.
Advancement of AEOL 20415 for Infectious Diseases: The global market for infectious disease treatments is driven by the emergence of new pathogens and the increasing prevalence of existing infections. Aeolus' development of AEOL 20415 provides an opportunity to address unmet needs in this market. Successful development and commercialization could lead to revenue growth. The timeline for this opportunity depends on clinical trial outcomes and regulatory approvals.
Strategic Partnerships and Collaborations: Aeolus could pursue strategic partnerships with larger pharmaceutical companies or government agencies to accelerate the development and commercialization of its drug candidates. Such partnerships could provide access to funding, expertise, and distribution channels, enhancing the company's growth prospects. The timeline for securing such partnerships is uncertain and depends on the attractiveness of Aeolus' pipeline and the willingness of potential partners.
Government Contracts for Biodefense: Given its focus on medical countermeasures, Aeolus could pursue government contracts for the development and supply of drugs to protect against nuclear, radiological, and chemical threats. Securing such contracts could provide a stable revenue stream and validate the company's technology. The timeline for securing government contracts depends on government priorities and procurement processes.

Aeolus Pharmaceuticals operates with a small team of 4 employees, indicating a lean operational structure.
The company's lead compound, AEOL 10150, has completed two Phase I clinical trials, marking progress in its development as a medical countermeasure.
Aeolus Pharmaceuticals is developing compounds for Parkinson's disease (AEOL 11114B, AEOL 11203, and AEOL 11207) and infectious diseases (AEOL 20415), expanding its therapeutic focus.
The company's negative profit margin of -171.4% reflects significant expenses relative to revenue, typical for early-stage biopharmaceutical companies.
Aeolus Pharmaceuticals has a negative Beta of -5.55, suggesting an inverse correlation with the market, although this may be less reliable due to its OTC status and limited trading volume.

AOLS提供哪些产品和服务？

Develop catalytic antioxidant compounds for medical countermeasures.
Create treatments for acute radiation syndrome.
Develop drugs for exposure to chemical vesicants and nerve agents.
Research treatments for diseases of the respiratory system.
Develop therapies for central nervous system disorders.
Develop oncology treatments.
Research treatments for Parkinson's disease.
Develop therapies for infectious diseases.

AOLS如何赚钱？

Develop novel pharmaceutical compounds.
Conduct preclinical and clinical trials to evaluate drug safety and efficacy.
Seek regulatory approval for drug candidates.
Potentially commercialize approved drugs through partnerships or direct sales.

Government agencies responsible for biodefense.
Hospitals and healthcare providers.
Patients suffering from targeted diseases.

Proprietary platform of catalytic antioxidant compounds.
Patents protecting drug candidates and technologies.
Expertise in developing medical countermeasures.
Specialized focus on niche disease treatments.

什么因素可能推动AOLS股价上涨？

Ongoing: Clinical trial progress for AEOL 10150 in treating acute radiation syndrome.
Ongoing: Development of AEOL 11114B, AEOL 11203, and AEOL 11207 for Parkinson's disease.
Ongoing: Advancement of AEOL 20415 for treating infectious diseases.
Upcoming: Potential government contracts for biodefense medical countermeasures.
Upcoming: Strategic partnerships with larger pharmaceutical companies.

AOLS的主要风险是什么？

Ongoing: Negative profit and gross margins indicating financial instability.
Potential: Clinical trial failures leading to loss of investment.
Potential: Regulatory hurdles and delays in drug approval processes.
Ongoing: Competition from larger pharmaceutical companies with greater resources.
Potential: Funding challenges and potential for dilution of existing shareholders.

AOLS的核心优势是什么？

Proprietary platform of catalytic antioxidant compounds
Lead compound (AEOL 10150) with completed Phase I clinical trials
Focus on biodefense and niche disease treatments
Potential for government contracts and partnerships

AOLS的劣势是什么？

Negative profit and gross margins
Limited financial resources
Small team and operational scale
OTC listing with associated liquidity risks

AOLS有哪些机遇？

Advancement of AEOL 10150 through clinical trials and regulatory approval
Expansion into Parkinson's disease and infectious disease treatments
Strategic partnerships with larger pharmaceutical companies
Government contracts for biodefense

AOLS面临哪些威胁？

Clinical trial failures
Regulatory hurdles and delays
Competition from larger pharmaceutical companies
Funding challenges and dilution

AOLS的竞争对手是谁？

Count Pharma Inc — Focus on generic pharmaceuticals. — (CNTTQ)
Dizenco Inc — Develops and markets specialty pharmaceutical products. — (DZCA)
Health Canada — Regulatory agency, not a direct competitor. — (HCANF)
Lowell Farms Inc — Cannabis company, different therapeutic area. — (LOWLF)
iAnthus Capital Holdings Inc — Cannabis company, different therapeutic area. — (MPXOF)

Key Metrics

MoonshotScore: 47/100

Company Profile

CEO: Christopher Stanley
Headquarters: Mission Viejo, US
Employees: 4
Founded: 1996

AI Insight

AI analysis pending for AOLS

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Aeolus Pharmaceuticals, Inc. do?

Aeolus Pharmaceuticals, Inc. is a biopharmaceutical company that develops a platform of novel catalytic antioxidant compounds. These compounds are designed for use in biodefense, specifically as medical countermeasures against nuclear, radiological, and chemical weapons. Additionally, they are being developed for the treatment of diseases and disorders of the respiratory system, central nervous system, and oncology. The company's lead compound, AEOL 10150, targets acute radiation syndrome and chemical weapon exposure.

What do analysts say about AOLS stock?

AI analysis is currently pending for AOLS. Given Aeolus Pharmaceutical's OTC listing and small market capitalization, formal analyst coverage may be limited. Investors should conduct their own due diligence, focusing on clinical trial progress, regulatory milestones, and financial stability. Key valuation metrics are difficult to assess due to the company's early stage and negative profitability. Growth considerations depend heavily on the successful development and commercialization of its drug candidates.

What are the main risks for AOLS?

The main risks for Aeolus Pharmaceuticals, Inc. include the inherent uncertainties of drug development, such as clinical trial failures and regulatory hurdles. The company's limited financial resources and negative profit margins pose a significant risk to its ability to fund ongoing research and development. Competition from larger pharmaceutical companies with greater resources is also a major concern. Additionally, the company's OTC listing exposes it to liquidity risks and potential price volatility.